Insulin glargine use and short-term incidence of breast cancer — a four-year population-based observation

Figures & data

Table I. Incidence rate ratio of breast cancer among users of insulin glargine compared with users of other types of insulins and not insulin glargine. Adjusted for age.

	2006–2007		2006–2008		2006–2009		2007–2009		2008–2009
	Cases	IRR (CI 95%)	Cases	IRR (CI 95%)	Cases	IRR (CI 95%)	Cases	IRR (CI 95%)	Cases	IRR (CI 95%)
Exp 2005*
Glargine alone	25	2.0 (1.3–3.0)	31	1.6 (1.1–2.3)	38	1.5 (1.1–2.1)
Glargine in combination	41	1.1 (0.8–1.5)	59	1.0 (0.7–1.3)	85	1.1 (0.8–1.4)
Any glargine use	66	1.3 (1.0–1.8)	90	1.1 (0.9–1.5)	123	1.2 (1.0–1.5)
Exp 2006*
Glargine alone							22	1.1 (0.7–1.8)
Glargine in combination							67	1.3 (1.0–1.7)
Any glargine use							89	1.2 (1.0–1.6)
Exp 2007*
Glargine alone									7	0.5 (0.2–1.1)
Glargine in combination									58	1.7 (1.2–2.3)
Any glargine use									65	1.3 (1.0–1.8)

*Filled prescriptions of glargine and other insulin during July to December the corresponding year.dfsd. CI, confidence interval; IRR, incidence rate ratio.